June 2025 in “British Journal of Dermatology” JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
December 2022 in “Sudan Journal of Medical Sciences” Vaccination is the most effective way to reduce COVID-19 transmission.
1 citations
,
December 2017 in “Dermatology - Open Journal” Alopecia areata was successfully treated with contact immunotherapy, oral antihistamines, and topical corticosteroids.
May 2025 in “Frontiers in Pharmacology” Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.
9 citations
,
August 2023 in “Molecules” Two peptides, RMYYY and VMYMI, may be effective anti-inflammatory drugs.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
July 2024 in “Medical alphabet” JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
January 2018 in “Journal of Investigative Dermatology” Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.
2 citations
,
September 2022 in “Frontiers in Immunology” T-regulatory cells are important for skin health and can affect hair growth and reduce skin inflammation.
July 2025 in “Journal of Dermatology Research Reviews & Reports” Exosomes show promise as effective treatments for autoimmune skin diseases with fewer side effects.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
27 citations
,
June 2017 in “Expert opinion on investigational drugs” New anti-acne medications are being tested to offer alternatives to current treatments.
1 citations
,
September 2004 in “Experimental Dermatology” MC-1R is present in skin cells and may help reduce inflammation.
January 2026 in “Clinical & Translational Oncology” Early intervention and tailored management are crucial for skin side effects in cancer treatments.
7 citations
,
January 2022 in “Biomedicines” Cells from the lower part of hair follicles are a promising, less invasive option for immune system therapies.
August 2018 in “Reactions Weekly” Two men experienced hair regrowth while being treated with immune globulin for other health issues, but there were also side effects.
1 citations
,
January 2023 in “Cutis” You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
November 2025 in “FEBS Open Bio” JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.
1 citations
,
March 2024 in “Signal transduction and targeted therapy” NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
9 citations
,
January 2018 in “Acta dermato-venereologica” A substance called poly(I:C) increases a protein called carbonic anhydrase II in skin cells, which might help with skin defense and healing.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
42 citations
,
January 2019 in “Frontiers in Immunology” A blood pressure drug, diltiazem, may also help treat influenza.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” DHT may reduce inflammation caused by certain bacteria in skin cells.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
Ivarmacitinib effectively regrows hair in severe alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.